Evidence map›Paper›PMID 33885949›Full record

ArticleZeitschrift fur Rheumatologie2021

[Myofasciitis under nivolumab treatment].

M Krusche, U Schneider, C Geisler, S Keller, W Stenzel, S Ohrndorf

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M KruscheMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland. martin.krusche@charite.de.ORCID http://orcid.org/0000-0002-0582-7790
U SchneiderMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland.
C GeislerKlinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland.
S KellerKlinik für Radiologie, Charité - Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland.
W StenzelInstitut für Neuropathologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
S OhrndorfMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland.
Charité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 73-year-old female patient with malignant melanoma who developed rapidly progressive dermatosclerosis of the arms and legs as well as myalgia and flexion contractures during treatment with the immune checkpoint inhibitor nivolumab. The diagnosis of a myofasciitis was confirmed by imaging and biopsy. Following consultation with the treating dermato-oncologists nivolumab treatment was paused and treatment with methotrexate and prednisolone was initiated. Immune checkpoint inhibitors can induce a variety of immune-mediated side effects and can also imitate symptoms of rheumatological diseases. The occurrence of myofasciitis under immune checkpoint inhibition has been reported in the literature only in a few cases. Further oncological and rheumatological treatment management should be carried out in close interdisciplinary coordination.

Indexed as

Drug-Related Side Effects and Adverse ReactionsMelanomaMyositisAgedFemaleHumansMyalgiaNivolumabNivolumabCheckpoint inhibitorsEosinophiliaFasciitisIrAEsMyalgia contraction myositis

Identifiers

PMID33885949
PMCPMC8575749
OpenAlexW3152541245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.